Moderna to share latest research across its mRNA vaccine portfolio, including influenza, RSV and COVID-19, at IDWeek 2025

Moderna, Inc. (announced data regarding two of its investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. The details of the presentations are as follows:

• Late-Breaking Oral Presentation #229: mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years: The presented data show the relative vaccine efficacy (rVE) of mRNA-1010 for the prevention of influenza compared to a licensed standard dose (SD) influenza vaccine. rVE was 26.6% (95%CI: 16.7%, 35.4%) in the overall study population, meeting the prespecified superiority criteria. rVE was consistent across vaccine-included strains, including Influenza B strains. mRNA-1010 also protected against more severe, including medically-attended influenza, with an rVE of 33.7% (95%CI: 12.0, 50.0%) compared to a licensed SD influenza vaccine. mRNA-1010 was well-tolerated, with no safety concerns identified. Injection site pain was the most common local solicited adverse reactions (SARs), and fatigue, headache and myalgia were the most common systemic SARs reported.
  • Presenter: Eleanor Wilson, MD, MHS
  • Time: Monday, October 20, 3:15-4:30pm ET
  • Location: B401-B402
• Oral Presentation #220: Safety and Immunogenicity of mRNA-1018, a candidate vaccine for the prevention of H5N1 pandemic influenza, in healthy adults ≥18 years of age in a dose-ranging Phase 1/2 clinical study: The presented data show that across all dose levels, mRNA-1018 was well-tolerated with no safety concerns identified, and demonstrated rapid and persistent immune response. Three weeks after the second dose, the immune responses in 97.8% of participants (95%CI: 95.4, 99.2) were at or above levels considered protective from influenza. Notably, as soon as three weeks after the first dose, immune responses at or above the accepted threshold for protection were observed in 79.5% (95%CI: 74.3, 84.1) of participants and six months after the second dose, 70.6% (95%CI: 64.8, 76.0) maintained seroprotective titers.
  • Presenter: Brett Leav, MD
  • Time: Monday, October 20, 3:15-4:30pm ET
  • Location: B207-B208

Moderna will also present the following:

• Oral Presentation #90: Interim Assessment of Safety and Immunogenicity from a Proof-of-Concept Phase 2 Trial of an mRNA-Based Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation
  • Presenter: Lori Panther, MD, MPH
  • Time: Monday, October 20, 10:30-11:45am ET
  • Location: B211-B212
• Oral Presentation #223: Safety, Tolerability, and Immunogenicity of the mRNA-1345 RSV Vaccine in Solid Organ Transplant Recipients Aged ≥18 Years
  • Presenter: Eric F. Mayer, MD
  • Time: Monday, October 20, 3:15-4:30pm ET
  • Location: B207-B208
• Late-Breaking Oral Presentation #407: Cardiac Troponin I Levels Following mRNA-1273 Vaccination in Participants 12 Through 30 Years of Age: Results from a Phase 4 Randomized, Placebo-Controlled Study
  • Presenter: Spyros Chalkias, MD
  • Time: Tuesday, October 21, 1:45-3:00pm ET
  • Location: B401-B402
• Oral Presentation #563: Safety and Immunogenicity of mRNA-1273.815 in COVID-19 Vaccine-Naïve Children 2 Through 4 Years of Age: Results from a Phase 3, Open-Label Trial
  • Presenter: Avika Dixit, MBBS
  • Time: Wednesday, October 22, 10:30-11:45am ET
  • Location: B207-B208
• Oral Presentation #642: mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Trial
  • Presenter: Anna Wald, MD, MPH
  • Time: Wednesday, October 22, 1:45-3:00pm ET
  • Location: B211-B212